REDWOOD CITY, Calif., March 11, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced that Charles P. Hart, Ph.D., Vice President of Biology, will present at the New York Academy of Sciences Conference on Saturday, March 14, at 4:30 p.m. Eastern Time. The conference will take place at the New York Academy of Sciences Conference Center in New York City.
The title of the conference, which will bring together clinicians and researchers from various areas of medicine, is Hypoxia and Consequences: From Molecule to Malady. Oxygen deprivation, or hypoxia, is a universal property of solid tumors and the target of Threshold's Phase 1/2 clinical candidate, TH-302. The title of Dr. Hart's presentation will be Targeting Pathophysiological Hypoxia in Cancer with the Hypoxia-Activated Prodrug (HAP) TH-302. The Company is conducting clinical trials investigating TH-302 as a monotherapy and in combination with four different chemotherapy regimens in cancer patients with solid tumors.
About Threshold Pharmaceuticals
Threshold is a biotechnology company focused on the discovery and development of small molecule therapeutics for the potential treatment of cancer. By selectively targeting abnormally-proliferating tumor cells, the Company's drug candidates are designed to be potentially more effective and less toxic to healthy tissues than conventional treatments. For additional information, please visit our website (www.thresholdpharm.com).